![vuze transcoder update vuze transcoder update](https://www.digitalproduction.com/wp-content/uploads/2019/11/handbrake-update.jpg)
Report topline data readout from the Phase 0 trial.Obtain institutional review board approval of our FIH Phase 0 clinical study at the center where we plan to conduct the trial in up to 12 cancer patients with advanced solid tumors.
![vuze transcoder update vuze transcoder update](https://niagara-video.com/wp-content/uploads/2017/10/9200-1024x260.png)
TransCode’s goals to continue to advance its portfolio include: Moved into new lab and office facilities in Newton, MA.Reported successful proof-of-mechanism studies using our immunotherapy candidate and began preclinical animal studies in melanoma.We believe this approach is advantageous over small molecules or antibodies because use of siRNA to inhibit the target antigen at the post-transcriptional level rather than at the protein level, means that the antigen is never synthesized by the cell In contrast to traditional monoclonal antibody checkpoint inhibitors, TTX-siPDL1 is designed to inhibit PD-L1 expression on tumor cells post-transcriptionally via the RNA interference mechanism. Positive preclinical results in pancreatic cancer.Received second ODD from FDA, for TTX-MC138 in pancreatic cancer.Positive preclinical results with TTX-MC138 in pancreatic adenocarcinoma 40% of animals treated with TTX-MC138 had complete responses, defined as complete regression of disease and long-term survival without recurrence.Significant progress toward completion of IND-enabling studies to support filing an IND application for a Phase I/2 clinical trial with TTX-MC138.Frank Slack (Director of the HMS Initiative for RNA Medicine) to our scientific advisory board Expanded our RNA oncology patent portfolio.Achieved positive preclinical results in pancreatic cancer with both TTX-MC138 and TTX-SiPLDL1.
![vuze transcoder update vuze transcoder update](https://www.snapfiles.com/screenfiles/vuze2.jpg)